The HIP1 Knockout A-549 Polyclonal Cells product comprises a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human A-549 lung adenocarcinoma cell line, engineered for targeted disruption of the HIP1 gene. This polyclonal format delivers a heterogeneous pool of cells harboring diverse loss-of-function edits across the HIP1 locus, enabling robust and reproducible in vitro modeling without requiring single-cell clonal isolation. The pooled nature preserves biological variability that more closely mimics heterogeneous tumor cell populations, making it suitable for investigating broad endocytic and signaling phenotypes under physiologically relevant conditions. Researchers employing this model gain a versatile tool for dissecting HIP1-dependent processes in epithelial cancer biology, drug response, and receptor trafficking, with applicability across standard molecular and cellular assay platforms.
A-549 cells constitute a widely characterized epithelial cell line originally established from explant culture of human lung adenocarcinoma tissue. These adherent cells retain multiple features of type II pulmonary alveolar epithelium, such as lamellar body formation and surfactant synthesis capacity, while exhibiting hallmark oncogenic traits including KRAS G12S mutation and loss of CDKN2A. The cells display robust clathrin-mediated endocytosis and active EGFR signaling, rendering them an appropriate host for interrogating the functional consequences of HIP1 disruption on receptor internalization and downstream cascades. Their well-documented growth kinetics and amenability to transfection, lentiviral transduction, and CRISPR-based editing further underpin the A-549 background as a reliable platform for generating gene-knockout derivatives employed in drug discovery and mechanism-of-action studies.
HIP1 encodes an endocytic adaptor protein that couples clathrin coats to the actin cytoskeleton during vesicle formation and scission, thereby facilitating the internalization of cargo such as the epidermal growth factor receptor (EGFR). HIP1 binds directly to clathrin heavy chain, the AP-2 complex subunit mu, and actin filaments, while also engaging Huntingtin (HTT), androgen receptor, and other regulators. Upstream, EGF stimulation and cellular stress signals promote HIP1 recruitment to nascent pits; downstream, HIP1 drives EGFR degradation and modulates androgen receptor transcriptional activity, ultimately influencing caspase-3 activation in apoptotic pathways. Consequently, HIP1 operates at the intersection of clathrin-mediated endocytosis, EGFR signaling, androgen receptor signaling, and apoptosis regulation, with functional links to Huntington disease, non-small cell lung cancer, prostate cancer, and colorectal cancer.
Within the A-549 cellular context, constitutive EGFR signaling constitutes a major driver of proliferation and survival, making the pathway highly susceptible to alterations in receptor internalization rates. HIP1 knockout in this background is predicted to attenuate EGFR uptake, leading to sustained surface receptor levels, protracted ERK and AKT phosphorylation, and potential changes in cell cycle progression and apoptotic threshold. Moreover, disrupted HIP1 function may uncouple endocytic sorting from actin dynamics, affecting cell adhesion, migration, and vesicular trafficking genome-wide. These phenotypes provide a tractable system for experimentally addressing how endocytic adaptors tune oncogenic signaling strength, influence therapeutic responses to EGFR inhibitors, and intersect with stress-induced apoptosis, a node frequently dysregulated in therapy-resistant lung adenocarcinoma.
Typical applications include immunofluorescence-based visualization of clathrin-coated puncta, EGFR internalization time-course assays, and flow cytometric quantification of surface receptor retention following HIP1 disruption. Co-immunoprecipitation protocols can map altered protein interactions involving clathrin, AP-2, and HTT, while Annexin V apoptosis assays and MTT proliferation measurements assess HIP1-dependent survival effects. Migration and wound-healing assays evaluate motility changes linked to endocytic adaptor loss. Collectively, the HIP1 Knockout A-549 Polyclonal Cells enable systematic investigation of endocytosis-regulated signaling in lung cancer, serving as a platform for identifying novel modulators of receptor trafficking and for evaluating compound sensitivity in a gene-disrupted epithelial background. For further technical details and ordering information, please contact Ascent Research.
